Sbir phase II - enhanced overall survival in high-risk pediatric solid tumors using a novel oral small molecule
Active Definitive Contract Awarded Last action
- Contract number
- 75N91025C00051
- Awardee
-
Novomedix LLC UEI XQYMHKGDMU75
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,977,013
Award facts
- Opportunity
-
- 75N91024R00019 Solicitation number
- Contract value 100% obligated
- $2,977,013.00 Current and potential, with all options
- Completion date 56% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 16 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92126, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $2,977,013 |
About this award
The National Cancer Institute awarded a $2,977,013 firm fixed-price definitive contract to Novomedix LLC, a woman-owned small business, on September 15, 2025, under a total small business set-aside. The contract funds SBIR Phase II research into enhanced overall survival in high-risk pediatric solid tumors using a novel oral small molecule therapeutic.
Place of performance is San Diego, CA. The ultimate completion date is September 14, 2027. This Phase II award builds on a prior Phase I concept award, advancing the company's pediatric oncology research program within the National Cancer Institute's Small Business Innovation Research portfolio.
Quick answers
Who was awarded contract 75N91025C00051?
75N91025C00051 was awarded to Novomedix LLC by National Cancer Institute (National Institutes of Health) on September 15, 2025.
How much is contract 75N91025C00051 worth?
The government has obligated $2,977,013 on 75N91025C00051.
Was contract 75N91025C00051 competed?
The extent of competition for 75N91025C00051 was full and open competition after exclusion of sources. The government received 16 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award